- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04215653
A Phase 3 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers.
December 30, 2019 updated by: Sihuan Pharmaceutical Holdings Group Ltd.
A Phase 3,Double-blinded, Double Dummy, Positive Drug, Parallel, Randomised Controlled Multicenter Trial to Evaluate Efficacy and Safety of Anaprazole Compared With Rabeprazole in Patients With Duodenal Ulcers.
A phase 3,double-blinded, double dummy, parallel, non-inferiority, randomised controlled multicenter trial to evaluate efficacy and safety of 4 weeks treatment of Anaprazole 20mg QD compared with rabeprazole 10mg QD in patients with duodenal ulcers.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
448
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18-70 years, male and female
- Has endoscopic diagnosis of active duodenal ulcer(s) (A1 or A2 stage) within 7 days prior to randomization
- 1 or 2 ulcers, 3-15 mm in diameter.
- Signed informed concent form
Exclusion Criteria:
- Has malignancy ulcer or malignancy ulcer not excluded, compouned ulcer, stress ulcer, esophageal erosion and ulcer, reflux esophagitis, Zollinger-Ellison syndrome.
- Has esophageal and gastric varices;
- With severe compliaction, such as pyloric obstruction, bleeding (Forrest I, IIa and IIb) or perforation, and etc;
- Has gastric ulcer, or has history of inflammatory bowel disease (such as Crohn's disease or ulcerative colitis);
- Has undergone surgical resection or partly resection of esophageal, stomach or duodenum;
- Has used Proton Pump Inhibitors(PPIs) within 5 days prior to randomization, or continuous more than 3 days of use of Proton Pump Inhibitors within 2 weeks prior to randomization;
- Has been treated with triple or quandruple Helicobacter pylori eradication therapy included PPIs within 28 days prior to randomization;
- Current use the drugs (such as systemic glucocorticoids, non steroid anti-inflammatory drugs, or anticoagulation drugs) which may induce ulcer or ulceric bleeding or continuous more than 3 days of use the drugs (such as systemic glucocorticoids, non steroid anti-inflammatory drugs, or anticoagulation drugs) within 28 days prior to randomization;
- Laboratory tests performed in screning stage revealed Alanine aminotransferase (ALT) or aspartate aminotransferase (AST): > 1.5 upper limit of normal (ULN);
- Laboratory tests performed in screning stage revealed thyroid stimulating hormone (TSH) or free triiodothyronine (FT3) and free thyroxin ( FT4) : > upper limit of normal (ULN);
- Woman in pregnancy or lactation period;
- Plan for pregancy or not willing to contracept with reliable contraception method during study period and within 90 days after the final time of investigational drug administratio;
- Have alcohol abuse or drug abuse 1 years prior to screening;
- Has hypersensitivity or allergy to investigatory drug, comparatory drug or related supplements;
- Has participated or been participating other clinical trials(non-interventional study is excluded);
- Has an uncotroled disease, such as has a history of significant central nervous system (CNS), cardiovascular, pulmonary, hepatic, renal, gastrointestinal, or mental or psychological disorders with drug treatment that,in the opinion of the investigator, would not be suitable for participating this clinical trial.
- Has a history of malignancy or was treated or not treated for malignancy within 5 years before randomization (the participant may be included in the study if he/she has cured cutaneous basal cell carcinoma), no matter if there is evidence for local relapse or metastasis;
- Laboratory tests performed in screning stage revealed estimated Glomerular filtration rate(eGFR) <80 mL/min/1.73 m2 calculated by Modification of Diet in Renal Disease(MDRD) equation;
- In the opinion of the investigator, the patients with other situation would not be suitable for participating this clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Anaprazole Sodium + Rabeprazole Placebo
administered orally once every 30-60 minutes before breakfast for 4 weeks
|
administered orally once every 30-60 minutes before breakfast for 4 weeks
administered orally once every 30-60 minutes before breakfast for 4 weeks
|
Active Comparator: Rabeprazole +Anaprazole Sodium Placebo
administered orally once every 30-60 minutes before breakfast for 4 weeks
|
administered orally once every 30-60 minutes before breakfast for 4 weeks
administered orally once every 30-60 minutes before breakfast for 4 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The endoscopic healing rate of duodenal ulcers at week 4, evaluated by blinded independency central reading.
Time Frame: Treatment of 4 weeks
|
The endoscopic ulcer healing rate is defined as the percentage of patients healed (complete healing and significant response) in whom the endoscopic response of duodenal ulcers at week 4 has been evaluated by blinded independency central reading.
|
Treatment of 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The endoscopic healing rate of duodenal ulcers at week 4, evaluated by investigator reading.
Time Frame: Treatment of 4 weeks
|
The endoscopic ulcer healing rate is defined as the percentage of patients healed (complete healing and significant response) in whom the endoscopic response of duodenal ulcers at week 4 has been evaluated by investigators.
|
Treatment of 4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 20, 2020
Primary Completion (Anticipated)
February 15, 2021
Study Completion (Anticipated)
February 28, 2021
Study Registration Dates
First Submitted
December 30, 2019
First Submitted That Met QC Criteria
December 30, 2019
First Posted (Actual)
January 2, 2020
Study Record Updates
Last Update Posted (Actual)
January 2, 2020
Last Update Submitted That Met QC Criteria
December 30, 2019
Last Verified
November 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Diseases
- Peptic Ulcer
- Duodenal Diseases
- Ulcer
- Duodenal Ulcer
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Rabeprazole
Other Study ID Numbers
- 3571-DU-3001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duodenal Ulcer,DU
-
Sihuan Pharmaceutical Holdings Group Ltd.Completed
-
TakedaCompleted
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
The Catholic University of KoreaSt Vincent's Hospital; Bucheon St. Mary's HospitalUnknown
-
GlaxoSmithKlinePiramal Clinical Research (Hyderabad, India)Completed
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownBleeding Gastric Ulcer | Bleeding Duodenal UlcerChina
-
AstraZenecaCompletedZollinger-Ellison Syndrome | Reflux Esophagitis (RE) | Gastric Ulcer (GU) | Duodenal Ulcer (DU) | Anastomotic Ulcer (AU) | Non-erosive Reflux Esophagitis Disease (NERD)Japan
-
The Third Xiangya Hospital of Central South UniversityLivzon Pharmaceutical Group Inc.; Yung Shin Pharm. Ind. Co., Ltd.CompletedDuodenal Ulcer Due to Helicobacter PyloriChina
-
B.P. Koirala Institute of Health SciencesCompletedPerforated Duodenal UlcerNepal
Clinical Trials on Anaprazole Sodium
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealthy Male Volunteers
-
Sihuan Pharmaceutical Holdings Group Ltd.Unknown
-
Sihuan Pharmaceutical Holdings Group Ltd.Completed
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealthy Male Volunteers
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruitingGastrointestinal Diseases | Gastroesophageal Reflux | Esophageal Motility Disorders | Deglutition Disorders | Esophageal Diseases | Esophagitis | Reflux EsophagitisChina
-
Sihuan Pharmaceutical Holdings Group Ltd.Completed
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealthy VolunteersChina
-
Sihuan Pharmaceutical Holdings Group Ltd.Unknown
-
University of DelawareCompletedBlood Pressure | Cerebrovascular ReactivityUnited States
-
Institut d'Anesthesiologie des Alpes MaritimesUniversité de Nice Sophia Antipolis; Medical University of GrenobleCompleted